Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

716
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
716
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.8K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

4.5K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
4.5K
Autoimmune Disorders01:29

Autoimmune Disorders

2.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.1K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rheumatoid arthritis patients with low baseline Health Assessment Questionnaire scores have a risk of functional disability progression: a post hoc analysis of a nationwide longitudinal cohort in Japan.

Clinical and experimental rheumatology·2020
Same author

Reduction in the percentage of circulating variable delta 2 T cells in systemic lupus erythematosus.

Clinical immunology (Orlando, Fla.)·2020
Same author

Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene.

Rheumatology (Oxford, England)·2020
Same author

Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial.

Medicine·2020
Same author

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.

Medicine·2020
Same author

KN3014, a piperidine-containing small compound, inhibits auto-secretion of IL-1β from PBMCs in a patient with Muckle-Wells syndrome.

Scientific reports·2020

Related Experiment Video

Updated: Mar 19, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K

[Abatacept].

Naoki Iwamoto, Atsushi Kawakami

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |June 18, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Abatacept (ABT) effectively treats rheumatoid arthritis (RA) in patients with inadequate responses to other therapies. ABT demonstrates a favorable safety profile, particularly regarding serious adverse events and infections, aiding optimal biologic use.

    More Related Videos

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
    08:46

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

    Published on: November 12, 2019

    54.2K
    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
    09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    4.0K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
    10:10

    Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

    Published on: November 8, 2016

    9.3K
    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
    08:46

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

    Published on: November 12, 2019

    54.2K
    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
    09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    4.0K

    Area of Science:

    • Immunology
    • Rheumatology
    • Pharmacology

    Context:

    • Rheumatoid arthritis (RA) management involves various biologic agents.
    • Abatacept (ABT) is a selective T-cell costimulation modulator.
    • Treatment challenges include patients with inadequate responses to methotrexate (MTX) or TNF inhibitors.

    Purpose:

    • To review the efficacy and safety of Abatacept (ABT) in rheumatoid arthritis (RA) management.
    • To highlight ABT's utility in specific patient populations.
    • To compare ABT's safety profile with other biologics.

    Summary:

    • Abatacept (ABT), a fusion protein targeting T-cell activation, has shown efficacy in RA patients, including those with inadequate responses to MTX and TNF inhibitors.
    • Clinical trials support ABT's effectiveness in diverse RA patient subgroups.
    • A Cochrane review indicated ABT possesses a superior safety profile concerning serious adverse events and serious infections compared to other biologics.

    Impact:

    • Understanding ABT's efficacy and safety profile optimizes its clinical application in RA.
    • Provides evidence-based guidance for selecting biologics in RA treatment.
    • Contributes to improved patient outcomes through informed therapeutic choices.